secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001641172-25-009247
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow Q1 revenue $47.8M (+38% YoY); VEVYE revenue $21.5M (+35% QoQ); reaffirms >$280M FY2025 guidance
--------------------------------------------------------------------------------

- Revenues $47.8M, up 38% YoY; GAAP net loss $(17.8)M; adjusted EBITDA $(2.0)M.
- VEVYE revenue $21.5M (+35% QoQ); VAFA launch drove new RXs >4X and prescribers >4X at PhilRx.
- VEVYE new patent exp. 2042 added to Orange Book; second production site expected H1 2026.
- TRIESENCE received CMS pass-through status Apr 1; accounts ordering more than doubled since Jan.
- Refinancing $222.75M debt in active discussions; expect resolution by late summer/early fall.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000164117225009247/0001641172-25-009247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000164117225009247/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer